曲妥珠单抗生物仿制药对比原研药治疗复发或转移性HER-2阳性乳腺癌的药物经济学评价OA北大核心CSTPCD
Pharmacoeconomic evaluation of trastuzumab biosimilars versus original drug in the treatment of recurrent/metastatic HER-2 positive breast cancer
目的 从卫生体系角度评估曲妥珠单抗生物仿制药(汉曲优)与原研药(赫赛汀)治疗复发或转移性人表皮生长因子受体2(HER-2)阳性乳腺癌的经济性.方法 根据NCT03084237试验数据构建分区生存模型,模拟周期为3周,模拟时限为10年.以成本和质量调整生命年(QALY)为产出指标,采用成本-效用分析法评价上述2种方案的经济性.采用单因素敏感性分析和概率敏感性分析检验模型的稳健性.结果 曲妥珠单抗生物仿制药组与原研药组的成本分别为111 516.72…查看全部>>
OBJECTIVE To evaluate the cost-effectiveness of trastuzumab biosimilars(Hanquyou)versus original drug(Hesaiting)in the treatment of recurrent/metastatic human epidermal growth factor receptor-2(HER-2)positive breast cancer.METHODS A partitional survival model was constructed based on the NCT03084237 trial data.The simulation period was 3 weeks,and the simulation time was 10 years.Using costs and quality-adjusted life year(QALY)as the output indicator,the cos…查看全部>>
邢玥;刘通;滕雪;董梅
哈尔滨医科大学附属肿瘤医院药学部,哈尔滨 150081哈尔滨医科大学附属肿瘤医院药学部,哈尔滨 150081哈尔滨医科大学附属肿瘤医院药学部,哈尔滨 150081哈尔滨医科大学附属肿瘤医院药学部,哈尔滨 150081
药学
曲妥珠单抗人表皮生长因子受体2乳腺癌分区生存模型药物经济学成本-效用分析原研药生物仿制药
trastuzumabhuman epidermal growth factor receptor-2breast cancerpartitional survival modelpharmacoeconomicscost-utility analysisoriginal drugbiosimilars
《中国药房》 2024 (9)
1113-1117,5
黑龙江省卫生健康委科研课题(No.20221313010972)
评论